porozendoОстеопороз и остеопатииOsteoporosis and Bone Diseases2072-26802311-0716Endocrinology Research Centre10.14341/osteo2006242-45porozendo-4173Research ArticleСтатьиArticlesНОВЫЙ БИСФОСФОНАТ БОНВИВАДЛЯ ЛЕЧЕНИЯ ПОСТМЕНОПАУЗАЛЬНОГО ОСТЕОПОРОЗАNOVYY BISFOSFONAT BONVIVADLYa LEChENIYa POSTMENOPAUZAL'NOGO OSTEOPOROZATOROPTsOVAN V-NIKITINSKAYaO A-BENEVOLENSKAYaL I-20061508200692№2 (2006)4245Copyright © TOROPTsOVA N.V., NIKITINSKAYa O.A., BENEVOLENSKAYa L.I., 20062006TOROPTsOVA N.V., NIKITINSKAYa O.A., BENEVOLENSKAYa L.I.TOROPTsOVA N.V., NIKITINSKAYa O.A., BENEVOLENSKAYa L.I.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.osteo-endojournals.ru/jour/article/view/4173ReferencesБеневоленская Л.И. Бисфосфонаты в терапии и профилактике остеопороза. // Росс. pевматол., 1998, 2, 2-9.Беневоленская Л.И. Бисфосфонаты в терапии и профилактике остеопороза. // Росс. pевматол., 1998, 2, 2-9.Беневоленская Л.И. Бисфосфонаты и остеопороз. // Рук. по остеопорозу (под ред. Проф. Л.И. Беневоленской). БИНОМ, М., 2003, 196-216.Беневоленская Л.И. Бисфосфонаты и остеопороз. // Рук. по остеопорозу (под ред. Проф. Л.И. Беневоленской). БИНОМ, М., 2003, 196-216.Клинические рекомендации «Остеопороз. Диагностика, профилактика и лечение (ред. Л.И. Беневоленская, О.М. Лесняк). // М.: ГЭОТАР-Медиа. - 2005. - 171с.Клинические рекомендации «Остеопороз. Диагностика, профилактика и лечение (ред. Л.И. Беневоленская, О.М. Лесняк). // М.: ГЭОТАР-Медиа. - 2005. - 171с.Barrett J., Worth E., Bauss F., Epstein S. Ibandronate: a clinical pharmacological and pharmacokinetic update. // J. Clin. Pharmacol. 2004; 44:951-965.Barrett J., Worth E., Bauss F., Epstein S. Ibandronate: a clinical pharmacological and pharmacokinetic update. // J. Clin. Pharmacol. 2004; 44:951-965.Bauss F., Kling L., Sponer G. Comparison of continuous and ciclical administration of ibandronate on bone mass in ovariectomized rats. //Bone Miner.Res., 1996, 11 (suppl. 1), S336Bauss F., Kling L., Sponer G. Comparison of continuous and ciclical administration of ibandronate on bone mass in ovariectomized rats. //Bone Miner.Res., 1996, 11 (suppl. 1), S336Bauss F., Wagner M., Hothorn L.H. Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. // J. Rheumatol. 2002; 29:990-998.Bauss F., Wagner M., Hothorn L.H. Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. // J. Rheumatol. 2002; 29:990-998.Bauss F., Lalla S., Endele R. et al. The effects of treatment with ibandronate on bone mass, architecture, biomechanical properties and bone concentration of ibandronate in ovariectomized aged rats. // J. Rheumatol. 2002; 29:2200-2208.Bauss F., Lalla S., Endele R. et al. The effects of treatment with ibandronate on bone mass, architecture, biomechanical properties and bone concentration of ibandronate in ovariectomized aged rats. // J. Rheumatol. 2002; 29:2200-2208.Bauss F., Russel R.G. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. // Osteoporosis Int. 2004; 15: 423-433.Bauss F., Russel R.G. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. // Osteoporosis Int. 2004; 15: 423-433.Bidstrup B., Ise J., Huss H. et al. Total dose, and not dosing frequency, determines treatment response to ibandronate. // Osteopor. Int., 2000, 11(supl.1), S26Bidstrup B., Ise J., Huss H. et al. Total dose, and not dosing frequency, determines treatment response to ibandronate. // Osteopor. Int., 2000, 11(supl.1), S26Chesnut III C.H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. // J. Bone Miner. Res., 2004, 19, 1241-1249.Chesnut III C.H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. // J. Bone Miner. Res., 2004, 19, 1241-1249.Cooper C., Emkey R.D., McDonald R.H. et al. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. // J.Clin. Endocrinol. Metab., 2003, 88, 4609-15.Cooper C., Emkey R.D., McDonald R.H. et al. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. // J.Clin. Endocrinol. Metab., 2003, 88, 4609-15.Cranney A., Wells G., Willan A. et al. IX. Summary of metaanalyses of therapies for postmenopausal osteoporosis. // Endocr.Rev. 2002; 23:570-578.Cranney A., Wells G., Willan A. et al. IX. Summary of metaanalyses of therapies for postmenopausal osteoporosis. // Endocr.Rev. 2002; 23:570-578.Delmas P.D., R.R. Recker, Chesnut III C.H. et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. // Osteopor. Int., 2004, 15, 792-798.Delmas P.D., R.R. Recker, Chesnut III C.H. et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. // Osteopor. Int., 2004, 15, 792-798.Fleisch H. The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat. // Osteoporosis Int. 1996; 6: 166-170.Fleisch H. The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat. // Osteoporosis Int. 1996; 6: 166-170.Fleisch H. Bisphosphonates: mechanisms of action. // Endocr. Rev. 1998; 19:80-100.Fleisch H. Bisphosphonates: mechanisms of action. // Endocr. Rev. 1998; 19:80-100.Lalla S., Hothorn L.A., Hagg N. et al. Lifelong of high doses of ibandronate increases bone mass and maintains bone quality in lumbar vertebrae in rats. // Osteopor. Int., 1998, 8, 97-103.Lalla S., Hothorn L.A., Hagg N. et al. Lifelong of high doses of ibandronate increases bone mass and maintains bone quality in lumbar vertebrae in rats. // Osteopor. Int., 1998, 8, 97-103.Miller P.D., McClung M., Macovei I. et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. // J. Bone Miner. Res. 2005; 20: 1315-11322.Miller P.D., McClung M., Macovei I. et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. // J. Bone Miner. Res. 2005; 20: 1315-11322.Monier-Faugere M.C., Geng Z., Paschalis E.P. et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariectomized beagle dogs: effects on bone morthometry and mineral properties. // J. Bone Miner. Res. 1999; 14: 1768-1778.Monier-Faugere M.C., Geng Z., Paschalis E.P. et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariectomized beagle dogs: effects on bone morthometry and mineral properties. // J. Bone Miner. Res. 1999; 14: 1768-1778.Papapoulos S.E. Ibandronate: a potent new bisphosphonate in the management of postmenopausl osteoporosis. // IJCP, 2003; 57: 417-422.Papapoulos S.E. Ibandronate: a potent new bisphosphonate in the management of postmenopausl osteoporosis. // IJCP, 2003; 57: 417-422.Ravn P., Clemmesen B., Riis B.J., Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. // Bone, 1996, 19, 527-533.Ravn P., Clemmesen B., Riis B.J., Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. // Bone, 1996, 19, 527-533.Ravn P., Christiansen C., Baumann M.,Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: Prediction of bone mass changes during treatment. // Bone, 1998, 22, 559-564.Ravn P., Christiansen C., Baumann M.,Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: Prediction of bone mass changes during treatment. // Bone, 1998, 22, 559-564.Recker R.R., Stakkestad J.A., Weber T. et al. Non-vertebral fracture benefit from oral ibandronate administrated daily or with a unique drug-free interval: results from a pivotal phase III study in postmenopausal osteoporosis (PMO). // J. Bone Miner. Res. 2002; 17 (suppl. 1): S134 (Abstract 1038).Recker R.R., Stakkestad J.A., Weber T. et al. Non-vertebral fracture benefit from oral ibandronate administrated daily or with a unique drug-free interval: results from a pivotal phase III study in postmenopausal osteoporosis (PMO). // J. Bone Miner. Res. 2002; 17 (suppl. 1): S134 (Abstract 1038).Recker R., Weinstein R., Chesnut III C.H. et al. Long-term treatment with oral daily and intermittent ibandronate produces newly formed bone of normal quality in patients with postmenopausal osteoporosis. // Osteopor. Int. 2003; 14 (Suppl.7):S73 (Abstract P265).Recker R., Weinstein R., Chesnut III C.H. et al. Long-term treatment with oral daily and intermittent ibandronate produces newly formed bone of normal quality in patients with postmenopausal osteoporosis. // Osteopor. Int. 2003; 14 (Suppl.7):S73 (Abstract P265).Reginster J-Y., Wilson K.M., Dumount E. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the Monthly Oral Pilot Study. // J. Clin. Endocrinol.Metab. 2005; 90: 5018-5024.Reginster J-Y., Wilson K.M., Dumount E. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the Monthly Oral Pilot Study. // J. Clin. Endocrinol.Metab. 2005; 90: 5018-5024.Reginster J-Y., Adami S., Lakatos P. et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis. // Ann.Rheum. Dis. 2006; 65:654-661.Reginster J-Y., Adami S., Lakatos P. et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis. // Ann.Rheum. Dis. 2006; 65:654-661.Riis B.J., Ise J., von Stein T. et al. Ibandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. // J. Bone Miner. Res., 2001,16, 1871-1878.Riis B.J., Ise J., von Stein T. et al. Ibandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. // J. Bone Miner. Res., 2001,16, 1871-1878.Smith S.Y., Recker R.R., Hannan M. et al. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. // Bone 2003; 32:45-55.Smith S.Y., Recker R.R., Hannan M. et al. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. // Bone 2003; 32:45-55.
The authors declare that there are no conflicts of interest present.